Read Why BTIG Sees An Upside OF 55% In Pear Therapeutics

BTIG initiated coverage of Pear Therapeutics Inc PEAR with a Buy rating and $12 price target, representing an upside of almost 55%.

  • Analyst Marie Thibault believes Pear is one of the best-positioned companies in the prescription digital therapeutics space.
  • According to the analyst, the Company has a head start on a regulatory, commercial, and operational basis. Its PearCreate and PearConnect platforms are intended to iterate and distribute new PDTs rapidly.
  • Recently, Citi initiated coverage of Pear Therapeutics with a Buy rating and $13 price target. 
  • According to analyst Neena Bitritto-Garg, Pear is well-positioned to leverage a "first-mover advantage" in prescription digital therapeutics. 
  • While a reimbursement overhang could pressure the shares into 2022, a "reimbursement inflection point is approaching," and Pear has a path to "rapidly scale" with commercial and pipeline products once a streamlined regulatory framework for prescription digital therapeutics is in place in 2022 and 2023, says the analyst.
  • Price Action: PEAR shares are up 23.40% at $7.65 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorBiotechLong IdeasNewsHealth CareInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!